The pharmaceutical world offers a valuable blueprint on how to harness AI’s efficiency while protecting trust, ethics and above all, people.

A de facto “data tariff” regime is already emerging. It does not resemble customs duties levied at a port. Instead, it takes shape through regulatory tolls that determine who may transfer, process, or ...